Skip to Main content Skip to Navigation
Journal articles

Multi‐target anti‐EBV therapy for prevent primary infection in kidney transplant recipients from deceased donor, at risk of post transplantation lymphoproliferative disorder (EBV D+/R‐)

Abstract : If all immunocompromised patients can experience Post Transplantation Lymphoproliferative Disorder (PTLD) due to EBV reactivation, EBV-seronegative recipients in which primary infection can occur, are at higher risk of developing PTLD when transplanted with an organ from an EBV seropositive donor(1,2). In our center, among 73 EBV-seronegative adult patients transplanted between 2000 and 2016 (3% of the whole), 8 developed an early PTLD and 5 others beyond one year, all EBV-related(3). EBV is most often latent and inaccessible within B cells, but occasionally it achieves a lytic infection, susceptible to some antiviral drugs, such as (val)ganciclovir, and specific antibodies.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-02633092
Contributor : Sylvie Le Bihan <>
Submitted on : Wednesday, May 27, 2020 - 11:58:45 AM
Last modification on : Thursday, May 28, 2020 - 3:18:32 AM

Identifiers

Collections

Citation

Simon Ville, Jacques Dantal. Multi‐target anti‐EBV therapy for prevent primary infection in kidney transplant recipients from deceased donor, at risk of post transplantation lymphoproliferative disorder (EBV D+/R‐). Transplant International, Wiley, 2020, ⟨10.1111/tri.13652⟩. ⟨inserm-02633092⟩

Share

Metrics

Record views

20